UAE Oncology Clinical Trials Market Report 2022 to 2030

UAE Oncology Clinical Trials Market Analysis

$ 3999

The UAE oncology clinical trials market is projected to grow from $63.3 Mn in 2022 to $104.7 Mn by 2030, registering a CAGR of 6.5% during the forecast period of 2022-30. The market will be driven by the rising rate of cancer in the UAE and investments in developing healthcare infrastructure and research capabilities to support the field. The market is segmented by phase, study design, and indication. Some of the major players include Pfizer Inc, FHoffmann-La Roche Ltd & Julphar

ID: IN10AECT006 CATEGORY: Clinical Trials GEOGRAPHY: UAE AUTHOR: Vidhi Upadhyay

Buy Now

UAE Oncology Clinical Trials Market Executive Summary

The UAE oncology clinical trials market is projected to grow from $63.3 Mn in 2022 to $104.7 Mn by 2030, registering a CAGR of 6.5% during the forecast period of 2022-30. Over 400 clinical research trials are now underway in Abu Dhabi. According to Globocan 2020, out of a total population of 98,90,400 number of new cases of cancer in UAE was 4,807. 21.4% of which accounted for breast cancer, 10.6% for colorectal cancer, and 8.4% for thyroid cancer.

Oncology clinical trials entail evaluating novel cancer therapies or combinations of treatments to establish their safety and efficacy. A variety of clinical trials in cancer are now underway in the UAE, which is mainly undertaken by hospitals, research organizations, or pharmaceutical corporations. In recent years, the UAE has made considerable efforts in strengthening its healthcare infrastructure and research capacity, notably in cancer. To conduct clinical studies and enhance cancer treatment, the government has formed alliances with renowned international institutes.

Trials for new cancer drugs, studies of novel therapies such as immunotherapy, and investigations into the use of advanced technologies such as robotics and artificial intelligence in cancer treatment are among the clinical trials in oncology that have been conducted or are currently underway in the UAE. Various institutions such as Dubai Hospital, Tawam Hospital, Abu Dhabi National Cancer Institute, Gulf International Cancer Center & Mediclinic Middle East conduct clinical trials in oncology. The UAE has also developed regulatory frameworks to guarantee that clinical trials are done in an ethical and international standard manner. The Ministry of Health and Prevention, the country's regulatory authority, controls the approval and supervision of clinical studies in the UAE.

UAE oncology clinical trials market analysis

Market Dynamics

Market Growth Drivers

Cancer incidences in the UAE have increased in recent years, which has increased the need for additional clinical studies to evaluate novel therapies. The UAE has invested in cutting-edge technology like as robotics and artificial intelligence, which will fuel the rise of cancer clinical trials that use these technologies. In the UAE, there is a growing awareness of the advantages of clinical trials, which might motivate more patients to enroll in cancer clinical trials. The UAE government has shown a propensity to spend on healthcare infrastructure and research, which is expected to aid in the expansion of cancer clinical trials. The UAE has formed strategic alliances with prominent worldwide institutions to conduct clinical trials, which is expected to assist fuel the country's development in cancer clinical trials.

Market Restraints

Due to the UAE's tiny population, it may be challenging to enroll a sufficient number of patients for clinical studies. Clinical studies may be costly, and the expense of conducting cancer clinical trials in the UAE might limit expansion. Despite government support, funding for cancer clinical trials in the UAE may be restricted. Clinical trials are subject to regulatory regulations, and negotiating these procedures may be difficult and time-consuming, potentially limiting progress. There may be competition for patients and resources from other nations.

Competitive Landscape

Key Players

Pfizer Inc
FHoffmann-La Roche Ltd
Novartis AG
AstraZeneca
Sanofi S.A
Merck & Co Inc.
Bristol-Myers Squibb
Johnson & Johnson
Julphar (ARE)
Medpharma (ARE)

Notable Insights

In September 2021, AstraZeneca partnered with one of Abu Dhabi's premier health tech firms (G42 Healthcare) to strengthen clinical research and diagnostics frameworks in the UAE
March 2022, AstraZeneca will provide breakthrough cancer drugs to the UAE. Several of its phase 3 and 4 clinical studies have been conducted in partnership with renowned UAE healthcare businesses

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Clinical Trials Regulation in Country
1.6 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Market Size (With Excel and Methodology)
2.2 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation

6. Methodology and Scope

Oncology Clinical Trials Market Segmentation

By Phase (Revenue, USD Billion):

Phase I
Phase II
Phase III
Phase IV

By Study Design Outlook (Revenue, USD Billion):

Epilepsy
Parkinson's Disease (PD)
Huntington's Disease
Stroke
Traumatic Brain Injury (TBI)
Amyotrophic Lateral Sclerosis (ALS)
Muscle regeneration
Others

By Indication Outlook (Revenue, USD Billion):

Interventional
Observational
Expanded Access

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.